Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Roger87on Nov 18, 2015 1:11pm
319 Views
Post# 24301460

Valeant to offer cash, stock to keep staff after turmoil

Valeant to offer cash, stock to keep staff after turmoil
https://ca.reuters.com/article/businessNews/idCAKCN0T724Q20151118

(Reuters) - Valeant Pharmaceuticals International Inc VRX.TO will likely offer cash and stock incentives to more key U.S. staff as it aims to avoid mass departures from the heavily scrutinized company, a spokeswoman said on Wednesday.

Laval, Quebec-based Valeant partially uses stock to compensate employees, but shares have fallen more than 70 percent since early August over concerns about its use of a U.S. specialty pharmacy and price spikes for some of its drugs.

About 70 Valeant employees in key positions below the executive level are receiving cash and stock to stay with the company, and Valeant will likely offer the incentives to more U.S. staff in coming weeks, said Laurie Little, head of investor relations. She did not give details.

"In the U.S., definitely there has been some anxiety," Little said at a Jefferies investor conference in London. "Through this turmoil, we definitely don't want to see an exodus."

Little said employees outside the United States are feeling less pressure because Valeant is known by other names in some countries.

Valeant's previously undisclosed use of a specialty pharmacy, Philidor Rx Services, drew allegations from short-seller Citron Research last month that it was inflating revenues. The company has denied the allegations, but said it would sever ties with Philidor.

Valeant shares on Wednesday climbed 1.5 percent to $71.35 in New York morning trading.

<< Previous
Bullboard Posts
Next >>